Bioproduction of Neospora caninum: a proof-of- concept towards a scalable serum-free process
This study demonstrates the feasibility of a scalable, serum-free bioproduction process for the oncolytic protozoan *Neospora caninum* using industrial CHO-K1 cells and Advanced DMEM/F-12 medium, thereby addressing critical bottlenecks in standardization and regulatory compliance for its clinical translation as a cancer immunotherapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cancer immunotherapy is a field of medicine that seeks to turn the body's own defenses against tumors, training the immune system to recognize and destroy cancer cells. While scientists have long used viruses and bacteria to stimulate this response, a new frontier involves using single-celled parasites known as protozoa. These microscopic organisms, which naturally invade cells, have shown a surprising ability to kill cancer cells in animal studies, offering a potential new weapon against the disease. However, moving these parasites from a laboratory dish to a treatment for patients requires a massive shift in how they are grown. Currently, producing them relies on methods that are difficult to standardize, expensive, and dependent on animal products, which creates hurdles for safety and large-scale manufacturing. To make these treatments a reality, researchers must find a way to grow these parasites reliably without using animal-derived ingredients, ensuring the process is clean, consistent, and ready for the clinic.
In a recent study, researchers set out to solve this production puzzle for a specific parasite called Neospora caninum. This organism, which is closely related to the parasite that causes toxoplasmosis, has demonstrated potent effects against various tumors in mice, but its growth in the lab has been limited by traditional methods. The team, working at the University of Tours and collaborating partners, aimed to develop a scalable process that removes animal serum from the culture medium. Animal serum, a nutrient-rich fluid often derived from fetal cows, is commonly added to cell cultures to help them grow, but it introduces risks of contamination and variability that are unacceptable for medical manufacturing. The scientists tested two different types of mammalian cells, known as BHK-21 and CHO-K1, which are standard workhorses in the biopharmaceutical industry. They adapted these cells to grow in defined, animal-free liquids and then infected them with the parasite to see which combination would produce the most offspring.
The researchers discovered that while both cell types could support the parasite's growth without animal serum, one was significantly better than the other. The CHO-K1 cells, which are widely used to manufacture medicines, proved to be the superior host. When grown in a specific nutrient-rich liquid called Advanced DMEM/F-12, these cells allowed the parasite to multiply far more effectively than in other tested environments. The team also found that the number of parasites used to start the infection, a factor known as the multiplicity of infection, played a critical role. They determined that starting with a moderate number of parasites, rather than a very large or very small amount, yielded the best results. This balance allowed the host cells to grow strong enough to support the parasite's replication before the parasites eventually burst out of the cells to be harvested.
To understand how the parasite and the host cell interacted during this process, the scientists monitored the chemical changes in the culture liquid. They measured how much sugar the cells consumed and how much waste product, called lactate, they produced. They found that as the parasite multiplied, the cells consumed sugar faster and produced more lactate, indicating a high level of metabolic activity. Interestingly, the specific nutrient liquid used for the CHO-K1 cells helped keep these metabolic rates stable, even as the infection progressed. This stability suggests that the cells remained healthy and robust right up until the moment the parasites were ready to be collected. The study also confirmed that the parasites remained infectious throughout the process, a crucial requirement for their use in cancer therapy. By tracking the energy levels within the parasites, the team verified that they retained their ability to invade new cells, provided the entire production process was completed within a specific timeframe of six hours.
The team also explored whether they could grow these parasites on tiny beads suspended in liquid, a technique used to scale up production for industrial manufacturing. While this method worked successfully for a related parasite, Toxoplasma gondii, the researchers were unable to produce Neospora caninum using the same setup. This failure highlighted that even closely related organisms have different needs and that what works for one may not work for another. Despite this setback with the beads, the core findings of the study provide a clear path forward. The research demonstrates that it is possible to grow Neospora caninum in large quantities using industrial-grade cells and animal-free liquids. By identifying the right cell type, the optimal nutrient mix, and the ideal starting conditions, the scientists have created a proof-of-concept for a manufacturing process that is cleaner, more consistent, and ready for future scaling. This work lays the essential groundwork for turning a promising laboratory observation into a standardized, safe, and effective treatment for patients.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.